NasdaqCM - Nasdaq Real Time Price USD

Dyadic International, Inc. (DYAI)

Compare
1.0400 -0.0600 (-5.45%)
At close: 4:00 PM EDT
1.0700 +0.03 (+2.88%)
After hours: 4:27 PM EDT
Loading Chart for DYAI
DELL
  • Previous Close 1.1000
  • Open 1.1100
  • Bid 0.7920 x 200
  • Ask 1.3100 x 200
  • Day's Range 1.0000 - 1.1399
  • 52 Week Range 1.0000 - 2.6700
  • Volume 67,844
  • Avg. Volume 36,174
  • Market Cap (intraday) 30.657M
  • Beta (5Y Monthly) 0.74
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2700
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.00

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

www.dyadic.com

7

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DYAI

View More

Performance Overview: DYAI

Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DYAI
35.40%
S&P 500
20.81%

1-Year Return

DYAI
45.83%
S&P 500
34.38%

3-Year Return

DYAI
80.71%
S&P 500
32.18%

5-Year Return

DYAI
82.40%
S&P 500
94.56%

Compare To: DYAI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DYAI

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    32.43M

  • Enterprise Value

    27.89M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    17.65

  • Price/Book (mrq)

    10.23

  • Enterprise Value/Revenue

    15.46

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -46.28%

  • Return on Equity (ttm)

    -127.38%

  • Revenue (ttm)

    1.8M

  • Net Income Avi to Common (ttm)

    -7.74M

  • Diluted EPS (ttm)

    -0.2700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.1M

  • Total Debt/Equity (mrq)

    175.65%

  • Levered Free Cash Flow (ttm)

    -3.49M

Research Analysis: DYAI

View More

Company Insights: DYAI

Research Reports: DYAI

View More

People Also Watch